Two Sigma Advisers
VRDN icon

Two Sigma Advisers’s Viridian Therapeutics VRDN Stock Holding History

Two Sigma Advisers’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-93,800
Closed -$1.31M – 2654
2025
Q2 		$1.31M Sell
93,800
-99,500
-51% -$1.35M ﹤0.01% 1308
2025
Q1 		$2.61M Sell
193,300
-142,269
-42% -$2.42M 0.01% 1051
2024
Q4 		$6.43M Sell
335,569
-109,231
-25% -$2.38M 0.01% 619
2024
Q3 		$10.1M Sell
444,800
-81,900
-16% -$1.34M 0.02% 486
2024
Q2 		$6.85M Buy
526,700
+222,300
+73% +$3.08M 0.02% 655
2024
Q1 		$5.33M Buy
304,400
+204,100
+203% +$3.96M 0.01% 757
2023
Q4 		$2.18M Buy
100,300
+80,000
+394% +$1.26M 0.01% 1240
2023
Q3 		$311K Buy
20,300
+10,800
+114% +$206K ﹤0.01% 1968
2023
Q2 		$226K Buy
+9,500
New +$244K ﹤0.01% 2062

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Two Sigma Advisers's VRDN Position: Q3 2025 in Review

Two Sigma Advisers sold out of Viridian Therapeutics (VRDN) in Q3 2025, closing a stake of 93,800 shares — an estimated $1.31M sold.

Two Sigma Advisers first reported a position in VRDN in Q2 2023 and held it in 9 quarters. The position peaked at $10.1M in Q3 2024. 169 funds tracked by Wall St. Rank hold VRDN as of Q3 2025.

  • Two Sigma Advisers reported no remaining Viridian Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 93,800 Viridian Therapeutics shares in Q3 2025, an estimated $1.31M.
  • Two Sigma Advisers first reported a position in Viridian Therapeutics in Q2 2023 and held it in 9 quarters.
  • Two Sigma Advisers's Viridian Therapeutics position peaked at $10.1M in Q3 2024.
  • 169 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2025.

Based on Two Sigma Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.